Abstracts tagged "Therapy, complementary"

Abstract Number: 1178 • ACR Convergence 2024
Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?
Nancy Baker¹, Aliza Spielman¹ and Robert Edwards², ¹Tufts University, Medford, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a common and disabling condition characterized by widespread muscular pain. Meditation has been shown to alleviate affective pain in people with…
Abstract Number: 1217 • ACR Convergence 2024
Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California
Maggie Hui¹, Nicholas Jackson², Angela Pham¹, Keren Chen², David Elashoff², ziva Cooper³ and Veena Ranganath⁴, ¹David Geffen School of Medicine at UCLA, Los Angeles, ²UCLA Department of Medicine Statistics Core, Los Angeles, ³UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles, ⁴UCLA, Los Angeles, CA
Background/Purpose: Approximately 12-20% of Rheumatology patients use cannabis (Fitzcharles 2020, Wipfler 2022, Rampakakis 2023). Despite the legalization of medical cannabis in California more than 2…
Abstract Number: 1415 • ACR Convergence 2024
Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, Alan Baer², Thomas Grader-Beck³, Margaret Beach⁴, Blake M. Warner⁵, Christopher Lessard¹, A. Darise Farris¹ and Robert Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins, Baltimore, MD, ⁴NIH/NIDCR, Arlington, VA, ⁵National Institutes of Health, Bethesda, MD
Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…
Abstract Number: 1459 • ACR Convergence 2024
Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
Michael Nissen¹, Adrian Ciurea², Raphael Micheroli³, Eric Trunk⁴ and Delphine Courvoisier⁵, ¹Geneva University Hospital, Geneva, Switzerland, ²University Hospital Zurich, Zürich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Geneva University Hospital, Geenva, Switzerland, ⁵University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Kathryn Torok¹, Paulina Horvei¹, Franziska Rosser¹, Kirsten Rose-felker², Vibha Sood², Adam Olsen², Nicole Hogue², Vickie Vandergrift², Lauren Farver², Devin Mcguire², Jonathan Li³, Haley Havrilla², Jessie Alexander⁴, Shawna McIntyre² and Paul Szabolcs¹, ¹University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Stanford Children's Hospital, Palo Alto, CA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Timothy Demchak¹, Ernesto Leal-Junior², Neide Ribeiro², Heliodora Casalechi², Douglas Johnson³ and Shaiane Tomazoni⁴, ¹Indiana State University, Terre Haute, IN, ²Nove de Julho University, São Paulo, Brazil, ³Multi Radiance Medical, Solon, OH, ⁴University of Bergen, Bergen, Norway
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…
Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Pamela Gonzalez Manrique¹, Vinit Gilvaz², Ravinder Kaler³, Neha Batra³ and Anthony Reginato², ¹Roger Williams Medical Center, North Providence, RI, ²The Warren Alpert Medical School of Brown University, Providence, RI, ³Roger Williams Medical Center, Providence, RI
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…
Abstract Number: 1914 • ACR Convergence 2023
Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Cristina Corrales Selaya¹, David Martínez-Lopez², Diana Prieto-Peña¹, Fabricio Benavides¹, Jose Luis Martin-Varillas³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Emmanuel Massy¹, Etienne Mabrut¹, Sabine Mainbourg² and Cyrille Confavreux¹, ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ²Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
Abstract Number: 2493 • ACR Convergence 2023
Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Maxime Vignac¹, Dorian Nezam², François Grolleau³, Pauline Morel⁴, Dimitri Titeca-Beauport⁵, Stanislas Faguer⁶, alexandre Karras⁷, Justine Solignac⁸, Noémie Jourde-Chiche⁹, Francois Maurier¹⁰, Hamza Sakhi¹, Khalil El Karoui¹, Rafik Mesbah¹¹, Pierre Louis Carron¹², Vincent Audard¹, Didier Ducloux¹³, Romain Paule¹⁴, Jean-François Augusto¹⁵, Julien Aniort¹⁶, Aurélien Tiple¹⁶, Cédric Rafat¹, Xavier Puéchal¹⁷, Pierre Gobert¹⁸, Catherine Hanrotel¹⁹, Stéphane Bally²⁰, Nihal Martis²¹, Cécile-Audrey Durel²², Pascal Godmer²³, Aurélie Hummel²⁴, François Perrin²⁵, Antoine Néel²⁶, Claire De Moreuil²⁷, Tiphaine Goulenok²⁸, Dominique Guerrot²⁹, Aurelie Foucher³⁰, Alban DEROUX¹², Loic Guillevin³¹, Alexis REGENT³², Raphaël Porcher³ and Benjamin Terrier³³, ¹APHP, Paris, France, ²CH du Havre, Havre, France, ³Université Paris Cité, Paris, France, ⁴AURA Paris Plaisance, Paris, France, ⁵CHU Amiens, Amiens, France, ⁶CHU Toulouse, Toulouse, France, ⁷HEGP - APHP, Paris, France, ⁸APHM, Marseille, France, ⁹AP-HM, Marseille, France, ¹⁰Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹¹Boulogne Hospital (CH), Boulogne, France, ¹²CHU de Grenoble, Grenoble, France, ¹³CHU de Besançon, Besançon, France, ¹⁴Hôpital Foch, Paris, France, ¹⁵CHU d'Angers, Angers, France, ¹⁶CHU de Clermont Ferrand, Clermont Ferrand, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ¹⁸Clinique Rhône Durance, Avignon, France, ¹⁹CHU Brest, Brest, France, ²⁰CH Métropole Savoie, Chambery, France, ²¹CHU de Nice, Nice, France, ²²CHU Lyon, Lyon, France, ²³CH Bretagne Atlantique, Vannes, France, ²⁴CHU Necker, Paris, France, ²⁵CH Saint Nazaire, Saint Nazaire, France, ²⁶CHU de Nantes, Nantes, France, ²⁷CHU de Brest, Brest, France, ²⁸Assistance Publique Hopitaux de Paris, Paris, France, ²⁹CHU Rouen, Rouen, France, ³⁰CHU de la Réunion, Saint pierre, France, ³¹University Paris Descartes, Paris, France, ³²CHU Cochin, Université Paris Cité, Paris, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
Abstract Number: 0025 • ACR Convergence 2023
Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis
Kristin Wipfler¹, Joanna Zeiger², Adam Cornish¹ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabinoid receptor 2 (CB2) is a member of the cannabinoid receptor family and is encoded by the CNR2 gene. CB2 receptors are found primarily…
Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Chary Lopez-Pedrera¹, Beatriz Vellón², Mª Angeles Aguirre³, Ismael Sanchez-Pareja², Laura Muñoz-Barrera², Tomás Cerdó², Pedro Segui², Christian Merlo-Ruiz², Desiree Ruiz-Vilchez², Maria del Carmen Abalos-Aguilera⁴, Nuria Barbarroja⁵, Alejandro Escudero Contreras⁶, Rafaela Ortega-Castro² and Carlos Perez-Sanchez⁷, ¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵University of Cordoba, Córdoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷IMIBIC, Córdoba, Spain
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…
Abstract Number: 0687 • ACR Convergence 2023
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
Georgina Espigol-Frigole¹, Maria C Cid², Juliana Bordignon Draibe³, Maria Carmen Prados⁴, Elena Guillen⁵, Ana Huerta⁶, Javier Villacorta⁷, Cristina Vega⁸, Judith Martins⁹, Borja Gracia¹⁰ and Enrique Morales¹¹, ¹Autoimmune Diseases. Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Clinic Barcelona, Barcelona, Spain, ³Hospital Bellvitge, Barcelona, Spain, ⁴Hospital Torrecárdenas, Almeria, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Puerta de Hierro, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital La Paz, Madrid, Spain, ⁹Hospital de Getafe, Madrid, Spain, ¹⁰Hospital Lozano Blesa, Zaragoza, Spain, ¹¹Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: ANCA-associated vasculitis are chronic and relapsing diseases. Relapses are frequently associated with organ damage accrual as a consequence of disease activity or treatment-related side…
Abstract Number: 0860 • ACR Convergence 2023
Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation
Chandramohan Natarajan¹, Julia Lucchino¹, David Chenoff² and Yaakov Levine¹, ¹SetPoint Medical, Valencia, CA, ²SetPoint Medical, Sausalito, CA
Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].